however, primary lung abscess caused by HVKP is not common. Herein we present a case of primary and multiple lung abscess due to HVKP with capsule genotype K2 in slow-progressive clinical course.
loss of 5 kg during this time. Physical examination revealed only lack of breath sounds over the thorax on auscultation. Computed tomography of the chest showed multiple lung abscess particularly in upper lobes (chest X-ray film which conducted 6-month ago also revealed nodular lesion in right upper lobe in retrospective evaluation). No liver and kidney abscess was found in the CT series. Both sputum and bronchoalveolar lavage fluid confirmed capsulated gram-negative rods on Gram-stain, and that cultures yielded only K. pneumoniae. Isolate was positive for the HVKP phenotype (positive string test >5 mm). Genetic analysis identified this strain as K2 serotype and having rmpA, mrkD, entB, and iutA genes. Ampicillin/ sulbactam (ABPC/SBT) was immediately started and the patients is still being treated.
Results: It is noted that this case had a prolonged clinical course (more than 6 months) although HVKP was isolated. There was only one report regarding community-acquired lung abscess due to HVKP in Taiwan. Difference between the previous and present case are summarized in Table 1 , and characteristics of those strains are completely different. In addition, the association between lung abscess and HVKP serotype is still unknown.
Conclusion:
To be our knowledge, this is the first identified case of community-acquired primary lung abscess due to serotype K2 HVKP. Further investigation regarding the relationship between HVKP and lung abscess is needed. Methods: This retrospective study was conducted in a medical center from December 2012 to July 2015. Patients who fulfilled the 2006 ATS/IDSA diagnostic criteria for nontuberculous mycobacterial lung disease were enrolled, and categorized by whether they received anti-MAC treatment (e.g. combination of macrolides, rifamycins, ethambutol, fluoroquinolones or aminoglycosides) or not. Minimal inhibitory concentration (MIC) for each antibiotic was tested for all Mycobacterium chimaera isolates from their pulmonary specimens, and the susceptibility was defined according to the epidemiologic cutoff value by CLSI. Favorable clinical outcome was defined as patient survival, with culture conversion and radiographic resolution 1 year after diagnosis or treatment. Logistic regression was used to identify the independent factors associated with favorable clinical outcome.
Results: Among 28 patients, 17 (60.7%) of them were female. The mean age was 72.0 AE 13.5 years old. All of the Mycobacterium chimaera isolates were susceptible to clarithromycin and rifabutin, 10 (35.7%) were susceptible to amikacin. Under chest radiography and computed tomography follow-up, 6 (60%) of the 10 patients in the treatment group and 3 (16.7%) of the 18 patients in the non-treatment group had radiographic resolution (P = 0.035). The odds ratio of favorable outcome was 10.8 (95% CI, 1.1-106.7, P = 0.042) in patient with anti-MAC treatment in the multivariable analysis.
Conclusion: According to our study results, treatment with macrolides and rifamycins based regimen for pulmonary Mycobacterium chimaera disease led to improved clinical outcomes. Background and Aims: The number of immunocompromised patients keeps increasing and many of them will suffer from pulmonary infection. This study was undertaken to assess the impact of next generation sequencing assisted pathogenic detection in immunocompromised host with pulmonary infection.
Methods: A total of 72 immunocompromised patients diagnosed of pulmonary infection was admitted in this study. The intervention group consisted of 33 patients who received next generation sequencing assisted pathogenic detection and the rest 39 patients made up the nonintervention group who only received microscopic examination and microbial culture test. Outcomes accessed included significative positive rate, turn around time of results, hospital and intensive care unit length of stay, all-cause 28-day and 90-day mortality, and total hospital expenditures.
Results: Next Generation Sequencing Assisted Pathogenic Detection improved turn around time (74.09 h in the non-intervention group versus 60.14h in the intervention group, P < 0.01), significative positive rate (23.08% vs 63.64%, P < 0.001), 90-day mortality (41.03% vs 18.18%, P < 0.05). The intervention of this detection method remains a significant predictor of survival (OR, 0.176; 95% confidence interval [CI], 0.036~0.874) after multivariate logistic regression. There wasn't significant difference of mean hospital costs in the two groups.
Conclusion: Next Generation Sequencing Assisted Pathogenic
Detection resulted in significant improvements of clinical outcome in immunocompromised patients diagnosed of pulmonary infection. The intervention decreased turn around time of results increased the significative positive rate, decreased mortality risk while not increased mean hospital costs.
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